Pharmacological therapy is the cornerstone of management for patients with moderate to severe lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia who do not have absolute indications for surgery. The primary goals of medical management are to alleviate symptoms, improve quality of life, and prevent disease progression. The two main classes of medications used for the treatment of BPH are alpha-1 adrenergic antagonists (alpha-blockers) and 5-alpha reductase inhibitors (5-ARIs).
Alpha-1 Adrenergic Antagonists
Alpha-1 blockers are the most commonly prescribed medications for the initial treatment of LUTS due to BPH. They work by relaxing the smooth muscle in the prostate gland, prostatic urethra, and bladder neck, thereby reducing the dynamic component of bladder outlet obstruction. This leads to a rapid improvement in urinary flow and a reduction in symptoms. Several alpha-1 blockers are available, including both non-selective and selective agents.
- Non-selective alpha-1 blockers: Prazosin, Terazosin, and Doxazosin block both alpha-1a and alpha-1b adrenergic receptors. While effective, their lack of selectivity can lead to systemic side effects, particularly postural hypotension, dizziness, and fatigue, due to their effect on vascular smooth muscle.
- Selective alpha-1a blockers: Tamsulosin, Alfuzosin, and Silodosin have a higher affinity for the alpha-1a adrenergic receptors, which are predominantly located in the prostate and bladder neck. This selectivity results in a lower incidence of systemic cardiovascular side effects, making them a preferred choice for many patients.
5-Alpha Reductase Inhibitors
5-ARIs, such as Finasteride and Dutasteride, work by inhibiting the enzyme 5-alpha reductase, which is responsible for the conversion of testosterone to dihydrotestosterone (DHT) within the prostate. By reducing intraprostatic DHT levels, these agents induce apoptosis of prostatic epithelial cells, leading to a reduction in prostate volume. This addresses the static component of bladder outlet obstruction. The clinical effects of 5-ARIs are slower to manifest than those of alpha-blockers, often taking several months to become apparent. However, they have been shown to be effective in reducing the risk of BPH progression, including the risk of acute urinary retention and the need for surgery, particularly in men with larger prostates.
Combination Therapy
For patients with more severe symptoms and larger prostates, combination therapy with an alpha-blocker and a 5-ARI has been shown to be more effective than monotherapy with either agent alone. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that the combination of Doxazosin and Finasteride was superior to either drug alone in reducing the risk of overall clinical progression of BPH [14].
Other Pharmacological Agents
In addition to the primary classes of medications, other drugs may be used in specific clinical scenarios:
- Phosphodiesterase-5 (PDE-5) Inhibitors: Tadalafil, a PDE-5 inhibitor commonly used for erectile dysfunction, has also been approved for the treatment of LUTS due to BPH. It is thought to work by relaxing smooth muscle in the prostate and bladder.
- Anticholinergics and Beta-3 Agonists: For patients with persistent storage symptoms (urgency, frequency, nocturia) despite treatment with an alpha-blocker, the addition of an anticholinergic agent or a beta-3 agonist may be beneficial to address detrusor overactivity.
References
[14] McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Jr, Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Pearson, J. D., Tindall, D. J., & Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England journal of medicine, 349(25), 2387–2398.